An organic trading recovery (or possibly inorganic) Buy…
We write after recently banking an approaching 32% bid price to offer price gain on another company takeover approach. The company we now replace that with in the portfolio has already had takeover interest into early this year and its recently announced half-year results highlight why and suggest the shares are a Buy.


